8 recruiting, 5 active not recruiting, 2 completed, 1 not yet recruiting. 11 Phase 1, 9 Phase 2, 2 Phase 3.
Follow Golcadomide: new trials by email Literature Review of Golcadomide trials Research Report on Golcadomide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas Golcadomide, Pemetrexed, Rituximab - Large B-cell Lymphoma, Central Nervous System Lymphoma | Phase 1 | Not yet recruiting | Allison Winter | 18 | 2026-10-01 | 2026-08-21 |
| A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function Golcadomide - Kidney Failure, Chronic | Phase 1 | Recruiting | Bristol-Myers Squibb | 30 | 2026-09-08 | 2026-10-01 |
| A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas roginolisib, golcadomide, azacitidine - Peripheral T Cells Lymphoma (PTCL) | Phase 1 / Phase 2 | Recruiting | The Lymphoma Academic Research Organisation | 49 | 2025-08-20 | 2026-02-11 |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) Golcadomide, Rituximab, Lenalidomide - Follicular Lymphoma | Phase 3 | Recruiting | Celgene | 400 | 2025-07-28 | 2026-05-20 |
| Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy GOLCADOMIDE, Nivolumab - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | University of Pittsburgh | 2025-06-30 | 2026-04-13 | |
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Mayo Clinic | 41 | 2025-04-02 | 2026-10-20 |
| A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma Golcadomide, Rituximab, Cyclophosphamide - Lymphoma, Follicular | Phase 2 | Active not recruiting | Celgene | 95 | 2024-08-30 | 2026-07-31 |
| Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment BMS-986369 - Hepatic Impairment, Healthy Volunteers | Phase 1 | Completed | Celgene | 29 | 2024-08-15 | 2026-01-23 |
| Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma Golcadomide, Placebo, Rituximab - Large B-cell Lymphoma | Phase 3 | Active not recruiting | Celgene | 850 | 2024-06-19 | 2026-07-06 |
| Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse golcadomide - Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Recruiting | The Lymphoma Academic Research Organisation | 65 | 2024-06-14 | 2026-06-04 |
| A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants Itraconazole, Rifampin, Golcadomide - Healthy Volunteers | Phase 1 | Completed | Celgene | 35 | 2024-04-23 | 2024-09-27 |
| CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2024-01-29 | 2026-02-27 |
| A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas BMS-986458, Rituximab, Glofitamab/Obinutuzumab - Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 460 | 2023-12-29 | 2026-09-14 |
| A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) BMS-986369 - Relapsed or Refractory T-cell Lymphomas | Phase 1 / Phase 2 | Active not recruiting | Bristol-Myers Squibb | 83 | 2023-11-20 | 2026-10-07 |
| Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. golcadomide, Nivolumab 10 MG/ML, Rituximab - Follicular Lymphoma Stage II, Follicular Lymphoma Stage III | Phase 2 | Active not recruiting | Olivia Newton-John Cancer Research Institute | 40 | 2023-08-31 | 2026-10-16 |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma SC Mosunetuzumab, IV Glofitamab, Iberdomide - Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | Hoffmann-La Roche | 121 | 2022-10-26 | 2026-08-17 |
Lymphoma (4) · Lymphoma, Follicular (4) · Lymphoma, Non-Hodgkin (3) · Disease (1) · Immunoblastic Lymphadenopathy (1) · Kidney Failure, Chronic (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Liver Diseases (1) · Lymphoma, B-Cell (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Peripheral (1)
Celgene (5) · Bristol-Myers Squibb (3) · The Lymphoma Academic Research Organisation (2) · Allison Winter (1) · City of Hope Medical Center (1) · Hoffmann-La Roche (1) · Mayo Clinic (1) · Nathan Denlinger (1) · Olivia Newton-John Cancer Research Institute (1) · University of Pittsburgh (1)
United States (12) · France (6) · Italy (5) · Spain (5) · Australia (4) · Chile (4) · Germany (4) · Japan (4) · South Korea (4) · United Kingdom (4) · Brazil (3) · Canada (3) · China (3) · Greece (3) · Netherlands (3)
Allison M Winter, MD (1) · Claire Tiger, MD, PhD (1) · Eliza Hawkes, MBBS (1) · Natalie Galanina, MD (1) · Nathan Denlinger, DO, MS (1) · Tycel J Phillips (1)
2023 (2), P30CA033572 (1)